lunes, 10 de enero de 2022

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer - The Lancet Oncology

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer - The Lancet Oncology

No hay comentarios:

Publicar un comentario